July 17, 2025
Intangible Assets

To fight U.S. tariffs, Canada should suspend U.S. drug patents, expert says

Now that the Trump administration has imposed 25% tariffs on goods from Canada, the Canadian government is levying tariffs in return. But other measures are also being examined and one notion the Canadian government should consider is suspending patent rights held by U.S. companies, including pharmaceutical companies, according to Richard Gold, a professor of law

Read More
Operating Assets

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase

Read More
Fixed Assets

We’re A Little Worried About Acurx Pharmaceuticals’ (NASDAQ:ACXP) Cash Burn Rate

There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Read More